2,786 research outputs found

    Magnetic behavior of lamellar mnps3 and cdps3 composites with a paramagnetic manganese(iii) macrocyclic guest

    Get PDF
    Indexación: ScieloSix new composites derived from the intercalation of the MPS3 phases (M = MnII, CdIII) with the macrocyclic manganese(III) complex [MnL(H2O)2].NO3(H2O) (LH2 = Schiff base macrocyclic ligand derived from the condensation of 2-hydroxy-5-methy1-1,3-benzene-dicarbaldehyde and 1,2-diamine-benzene) were obtained by two different synthetic procedures: a conventional and a microwave assisted method. The composites [MnL]0.25K0.15Mn0.80 PS3(H2O)~1.0 (1), and [MnL]0.25K0.15Cd 0. 80PS3(H2O)~0.5 (2) were obtained by the conventional method, after stirring a suspension of the corresponding potassium precursor and the macrocyclic complex for two weeks, while [MnL]0.35K0.15Mn0.80 PS3(H2O)~1.0 (3) and [MnL]0.25K0.15Cd 0. 80PS3(H2O)~0.5 (4) after stirring for four weeks at room temperature. Using a microwave assisted reaction permitted to obtain in a shorter period of time as compared with the conventional method, composites [MnL]0.20K0.15Mn0.80 PS3(H2O)~1.0 (5) and [MnL]0.15K0.15Cd 0. 80PS3(H2O)~0.5 (6). All the M = MnII, MnIII composites show a bulk antiferromagnetic behavior. However, the spontaneous magnetization present at low temperature in the potassium precursor K0.40Mn0.80 PS3(H2O)~1.0 is observable in composite [MnL]0.20K0.15Mn0.80 PS3(H2O)~1.0 (5), while it is completely absent in composites [MnL]0.25K0.15Mn0.80 PS3(H2O)~1.0 (1) and [MnL]0.35K0.15Mn0.80 PS3(H2O)~1.0 (3). Keywords: Intercalation; MPS3 phases; MnIII macrocyclic complex; microwave assisted synthesis; magnetic properties

    Combination of common mtDNA variants results in mitochondrial dysfunction and a connective tissue dysregulation

    Get PDF
    Mitochondrial dysfunction can be associated with a range of clinical manifestations. Here, we report a family with a complex phenotype including combinations of connective tissue, neurological, and metabolic symptoms that were passed on to all surviving children. Analysis of the maternally inherited mtDNA revealed a novel genotype encompassing the haplogroup J - defining mitochondrial DNA (mtDNA

    Anaphylaxis to clavulanic acid: seven-year survey

    Get PDF
    info:eu-repo/semantics/publishedVersio

    Oxygen targets and 6-month outcome after out of hospital cardiac arrest: a pre-planned sub-analysis of the targeted hypothermia versus targeted normothermia after Out-of-Hospital Cardiac Arrest (TTM2) trial

    Full text link
    Background: Optimal oxygen targets in patients resuscitated after cardiac arrest are uncertain. The primary aim of this study was to describe the values of partial pressure of oxygen values (PaO2) and the episodes of hypoxemia and hyperoxemia occurring within the first 72 h of mechanical ventilation in out of hospital cardiac arrest (OHCA) patients. The secondary aim was to evaluate the association of PaO2 with patients' outcome. Methods: Preplanned secondary analysis of the targeted hypothermia versus targeted normothermia after OHCA (TTM2) trial. Arterial blood gases values were collected from randomization every 4 h for the first 32 h, and then, every 8 h until day 3. Hypoxemia was defined as PaO2 300 mmHg. Mortality and poor neurological outcome (defined according to modified Rankin scale) were collected at 6 months. Results: 1418 patients were included in the analysis. The mean age was 64 ± 14 years, and 292 patients (20.6%) were female. 24.9% of patients had at least one episode of hypoxemia, and 7.6% of patients had at least one episode of severe hyperoxemia. Both hypoxemia and hyperoxemia were independently associated with 6-month mortality, but not with poor neurological outcome. The best cutoff point associated with 6-month mortality for hypoxemia was 69 mmHg (Risk Ratio, RR = 1.009, 95% CI 0.93-1.09), and for hyperoxemia was 195 mmHg (RR = 1.006, 95% CI 0.95-1.06). The time exposure, i.e., the area under the curve (PaO2-AUC), for hyperoxemia was significantly associated with mortality (p = 0.003). Conclusions: In OHCA patients, both hypoxemia and hyperoxemia are associated with 6-months mortality, with an effect mediated by the timing exposure to high values of oxygen. Precise titration of oxygen levels should be considered in this group of patients. Trial registration: clinicaltrials.gov NCT02908308 , Registered September 20, 2016. Keywords: Cardiac arrest; Hyperoxemia; Hypoxemia; Mortality; Neurological outcom

    Ventilation management and outcomes in out-of-hospital cardiac arrest: a protocol for a preplanned secondary analysis of the TTM2 trial

    Full text link
    IntroductionMechanical ventilation is a fundamental component in the management of patients post cardiac arrest. However, the ventilator settings and the gas-exchange targets used after cardiac arrest may not be optimal to minimise post-anoxic secondary brain injury. Therefore, questions remain regarding the best ventilator management in such patients.Methods and analysisThis is a preplanned analysis of the international randomised controlled trial, targeted hypothermia versus targeted normothermia after out-of-hospital cardiac arrest (OHCA)–target temperature management 2 (TTM2). The primary objective is to describe ventilatory settings and gas exchange in patients who required invasive mechanical ventilation and included in the TTM2 trial. Secondary objectives include evaluating the association of ventilator settings and gas-exchange values with 6 months mortality and neurological outcome. Adult patients after an OHCA who were included in the TTM2 trial and who received invasive mechanical ventilation will be eligible for this analysis. Data collected in the TTM2 trial that will be analysed include patients’ prehospital characteristics, clinical examination, ventilator settings and arterial blood gases recorded at hospital and intensive care unit (ICU) admission and daily during ICU stay.Ethics and disseminationThe TTM2 study has been approved by the regional ethics committee at Lund University and by all relevant ethics boards in participating countries. No further ethical committee approval is required for this secondary analysis. Data will be disseminated to the scientific community by abstracts and by original articles submitted to peer-reviewed journals.Trial registration numberNCT02908308
    • …
    corecore